Inactive Instrument

IGI Laboratories, Inc. Nyse

Equities

US4495751095

End-of-day quote Nyse Other stock markets
- ^USD	-

2022	Teligent, Inc. Went Out of Business	CI
2022	Second Amended Liquidation Plan Approved for Teligent, Inc.	CI

IGI Laboratories : Ranked Number 256 Fastest Growing Company In North America On Deloitte 2014 Technology Fast 500(TM)

November 13, 2014 at 08:01 am EST

BUENA, N.J., Nov. 13, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced it ranked No. 256 on Deloitte's Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. IGI grew 382 percent from 2009 to 2013.

http://photos.prnewswire.com/prnvar/20130827/MM70487LOGO

"At IGI we are excited about our transition and transformation from 2009 to 2013 from a topical contract manufacturing company to a specialty generic pharmaceutical company and it is rewarding for our success in that transformation and revenue growth to be recognized with a prestigious Deloitte Technology Fast 500 Award," said Jason Grenfell-Gardner, IGI's President and CEO. "Our future is bright, as we continue to expand our product portfolio and execute our "TICO" strategy, focused on the topical, injectable, complex and ophthalmic generic pharmaceutical markets."

"The companies ranked on the 2014 Deloitte Technology Fast 500 continue to set the bar for their industry higher each year," said Eric Openshaw, vice chairman, Deloitte LLP and U.S. technology, media and telecommunications leader. "There are so many exciting products and smart thought leaders driving this list. We congratulate the Fast 500 companies and look forward to seeing them continue their momentum into 2015."

About Deloitte's 2014 Technology Fast 500(TM)
Technology Fast 500, conducted by Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies - both public and private - in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2009 to 2013.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company's operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years and be headquartered within North America.

About IGI Laboratories, Inc.
IGI Laboratories is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market.

Logo - http://photos.prnewswire.com/prnh/20130827/MM70487LOGO

SOURCE IGI Laboratories, Inc.

Latest news about IGI Laboratories, Inc.

Teligent, Inc. Went Out of Business	22-07-26	CI
Second Amended Liquidation Plan Approved for Teligent, Inc.	22-07-15	CI
Second Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-05-25	CI
Second Amended Joint Liquidation Plan Filed by Teligent, Inc.	22-05-24	CI
First Amended Disclosure Statement Approved for Teligent, Inc.	22-04-29	CI
First Amended Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-27	CI
Joint Liquidation Plan and Disclosure Statement Filed by Teligent, Inc.	22-04-08	CI
First Motion for Exclusivity Period Extension Approved For Teligent, Inc.	22-02-28	CI
Motion for Case Conversion Filed by Teligent, Inc.	22-02-22	CI
First Motion for Exclusivity Period Extension Filed by Teligent, Inc.	22-02-09	CI
Hikma Pharmaceuticals Closes $46 Million Purchase of Teligent's Canadian Assets	22-02-03	MT
Pharmaceutical Associates, Inc. completed the acquisition of Generic and Branded US Marketing Authorizations of Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Hikma Pharmaceuticals PLC completed the acquisition of Canadian assets of Teligent Inc from Teligent, Inc. (OTCPK:TLGT.Q).	22-02-02	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-19	CI
Motion for Asset Sale Approved for Teligent, Inc.	22-01-18	CI
London Shares to Open Higher as Traders Focus On Key Data	22-01-17	DJ
Hikma Pharmaceuticals to Enter Canadian Market With $46 Million Asset Acquisition	22-01-17	MT
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Asset Purchase Agreement Filed by Teligent, Inc.	22-01-16	CI
Hikma Pharmaceuticals PLC agreed to acquire Canadian assets of Teligent Inc. from Teligent, Inc. (OTCPK:TLGT.Q) for $45.7 million.	22-01-16	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-14	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI
Notice of Selection of Successful Filed for Teligent, Inc.	22-01-13	CI

Chart IGI Laboratories, Inc.

Duration

Period

More charts

Company Profile

Teligent, Inc. is a generic pharmaceutical company. The Company is focused on the development, manufacturing and marketing of a portfolio of generic pharmaceutical products under its own label and private label for other pharmaceutical companies in topical, injectable, complex and other dosage forms. It also provides contract development and manufacturing services to the prescription and over-the-counter (OTC) pharmaceutical and cosmetic markets. Under the Company's own label, it markets and sells generic topical, and generic and branded generic injectable pharmaceutical products in the United States. In the United States, the Company markets approximately 37 generic topical pharmaceutical products and one branded injectable pharmaceutical product. The Company's portfolio of hospital-based sterile injectable products, including cephalosporins, Cefotan (Cefotetan for Injection), Fortaz (Ceftazidime) and Zinacef (Cefuroxime Sodium).

Sector

More about the company